The Zacks Analyst Blog Highlights Tesla, Medtronic, IBM, Lowe’s Companies and Intuitive Surgical

For Immediate Release

Chicago, IL – April 28, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc.

TSLA

, Medtronic plc

MDT

, IBM Corp.

IBM

, Lowe’s Companies, Inc.

LOW

and Intuitive Surgical, Inc.

ISRG

.

Here are highlights from Wednesday’s Analyst Blog:


Top Stock Reports for Tesla, Medtronic and IBM

The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Tesla, Inc., Medtronic plc, and IBM Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see



all of today’s research reports here >>>


Shares of

Tesla

have outperformed the Zacks Automotive – Domestic industry over the past year (+30.6% vs. -9.7%). Despite severe chip shortages, Tesla put up an impressive Q1 show, beating both top-and bottom-line expectations, thanks to stellar deliveries of Models 3 and Y.

The Zacks analyst believes that the deliveries will see an annualized growth of around 50% over the next three years. Ex-government credits, Tesla’s gross margins reached 30% in Q1. This indicates that the supply-chain issues hitting the company are being passed along to the consumer.

Additionally, Tesla’s energy generation and storage revenues outlook is promising. While low Q2 deliveries from the Shanghai gigafactory could be a short-term headwind, we expect Tesla to deliver outsized returns in the long run on the back of production ramp-up and introduction of new models.

(You can



read the full research report on Tesla here >>>



)

Shares of

Medtronic

have outperformed the Zacks Medical – Products industry over the year-to-date basis (+4.4% vs. -14.6%). The company has registered organic growth in the Cardiovascular, Neuroscience and Diabetes segments. The company claims share gains in 60% of its businesses.

However, the sluggish top-line results reflect the unfavorable market impact of COVID-19 and health system labor shortages. CRDN sales decreased in the mid-single digits, given the impact of COVID-19 on PCI procedures. Also, there have been low double-digit organic declines in RGR with sales of ventilators declining in the high-fifties as demand returns to pre-pandemic levels.

(You can



read the full research report on Medtronic here >>>



)

Shares of

IBM

have outperformed the Zacks Computer – Integrated Systems industry over the past year (+4.4% vs. -5.2%). The Zacks analyst believes that the company is poised to benefit from strong demand for hybrid cloud and AI, driving growth in Software and Consulting.

Synergies from the Red Hat buyout are bolstering its competitive position in the hybrid cloud market. It is likely to gain from the robust adoption and broad-based availability of IBM Blockchain World Wire a blockchain-driven global payments network aimed at accelerating and optimizing cross-border payments.

However, stiff competition in the cloud computing market like Amazon Web Services and Microsoft Azure remains an overhang. Higher debt levels amid extensive restructuring activities pose a concern. High integration risk from continuous acquisition spree is another headwind.

(You can



read the full research report on IBM here >>>



)

Other noteworthy reports we are featuring today include Lowe’s Companies, Inc. and Intuitive Surgical, Inc.

Why Haven’t You Looked at Zacks’ Top Stocks?

Our 5 best-performing strategies have blown away the S&P’s impressive +28.8% gain in 2021. Amazingly, they soared

+40.3%, +48.2%, +67.6%, +94.4%,

and

+95.3%

. Today you can access their live picks without cost or obligation.




See Stocks Free >>


Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



[email protected]



https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss

.

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit


https://www.zacks.com/performance


for information about the performance numbers displayed in this press release.


5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.


Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report


To read this article on Zacks.com click here.


Zacks Investment Research